Study of Unani Formulation in High Blood Pressure

Effect of sumbul-ut-teeb as adjunct in the management of essential hypertension:A randomized controlled study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/011726

Enrollment

Registered

2018-02-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Essential Hypertension

Interventions

Intervention1: Sumbul-ut-teeb: Sumbul-ut-teeb Fine powder of Sumbul-ut-teeb 3gm will be given orally in capsules, daily in three divided doses for 28 days Control Intervention1: Wheat flour: Placeb

Eligibility

Inclusion criteria

Inclusion criteria: Patientâ??s age within the range of 35 to 70 years of either gender. Patients with stage I hypertension as per Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), systolic pressure140 to 159 mmHg and diastolic pressure 90 to 99 mmHg.Patients using

Exclusion criteria

Exclusion criteria: Secondary hypertension. Left ventricular hypertrophy and failure. Essential hypertension with ischemic heart disease. Essential hypertension with diabetes mellitus. Essential hypertension with chronic renal failure. Hypertension in pregnancy. Lactating mothers Patients using >= 3 antihypertensive drugs

Design outcomes

Primary

Measure	Time frame
Reduction in systolic and diastolic blood pressureTimepoint: Baseline and 28th day	—

Secondary

Measure	Time frame
Secondary outcome: Improvement in Quality of life Timepoint: 28 days	—

Countries

India

Contacts

Public ContactDr MD Ahmad Bhat

National Institute of Unani Medicine

drmuzaffar79@gmail.com8618643497

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026